Company intelligence / Profile preview

Runer Ophthalmic Drugs

Wuxi, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Runer Pharmaceutical is a clinical-stage biopharmaceutical company based in Wuxi, China, specializing in the research and development of innovative ophthalmic drugs. The company focuses on addressing significant unmet medical needs in eye care, including treatments for dry eye disease, glaucoma, and retinal disorders such as diabetic macular edema. Runer leverages its expertise in drug delivery and formulation to develop both small molecule and peptide-based therapies. Its pipeline includes several candidates in various stages of clinical development, aiming to provide more effective and convenient options for patients with chronic ocular conditions.

Therapeutic areas: Ophthalmology
Modalities: Small moleculePeptides
Industry: Biotech

Beyond the preview

Go deeper on Runer Ophthalmic Drugs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Runer Ophthalmic Drugs.

Explore the full profile